MedTrace Logo

Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection

NCT01114581 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2018-09-19

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.

Conditions

  • Acute Respiratory Infection

Interventions

DRUG

Mucinex

Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study

DRUG

Placebo

Placebo given as 2 tablets

Sponsors & Collaborators

  • Reckitt Benckiser LLC

    lead INDUSTRY

Principal Investigators

  • William Bennett, PhD · University of North Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01114581 on ClinicalTrials.gov